Alvaro Ferrer-Gomez - Publications

PSA Response as a Prognostic Marker in Metastatic Hormone-sensitive Prostate Cancer: Comparison with Tumor Volume (CHAARTED).

Journal: European urology open science

Published: May 01, 2026

Long-Term Functional Outcomes and Complications of Advance™/AdVance Xp™ Male Suburethral Slings in the Management of Post-Prostatectomy Incontinence: Multicentric Prospective Ten-Year Follow-Up Study.

Journal: Neurourology and urodynamics

Published: February 02, 2026

Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC study.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: October 31, 2025

External validation of the heidenreich criteria for patients with post-chemotherapy residual masses of non-seminomatous germ cell tumor.

Journal: The Canadian journal of urology

Published: July 09, 2025

PSA response to predict progression in metastatic hormone-sensitive prostate cancer (mHSPC) patients. When is the optimal time point?

Journal: Urologic oncology

Published: May 06, 2025

PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.

Journal: Urologic oncology

Published: February 13, 2025

ProsTAV, a clinically useful test in prostate cancer: an extension study.

Journal: World journal of urology

Published: April 19, 2024

Comparative evaluation of continence and potency after radical prostatectomy: Robotic vs. laparoscopic approaches, validating LAP-01 trial.

Journal: Surgical oncology

Published: March 17, 2024

Prostate cancer patients with lymphatic node involvement detected by immunohistochemistry. Is the effort worthwhile?

Journal: Urologic oncology

Published: December 13, 2023

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532).

Journal: European urology oncology

Published: October 30, 2023

Personalised indocyanine-guided lymphadenectomy for prostate cancer: a randomised clinical trial.

Journal: BJU international

Published: July 06, 2023

Sentinel Lymph Node Biopsy in Prostate Cancer: An Overview of Diagnostic Performance, Oncological Outcomes, Safety, and Feasibility.

Journal: Diagnostics (Basel, Switzerland)

Published: June 29, 2023